PT-141 / bremelanotide — what does the actual approved-drug evidence say vs. the hype?

Good instinct to be skeptical. The registrational trials (the RECONNECT program) were in premenopausal women with HSDD, and the improvements in desire and distress scores were statistically significant but clinically modest — the kind of effect where a meaningful minority of responders drives the average. Nausea was the standout side effect and a real driver of dropouts.

The broader 'works for everyone' framing is mostly mechanism-based extrapolation from how melanocortin-4 receptor activation affects central sexual pathways, plus scattered early-phase and anecdotal reports. That's not nothing, but it's a very different evidence tier than a completed phase 3 program. Treat the universal claims as hypotheses, not established fact.

Anecdotally — and purely as my own experience, not a recommendation — the nausea for me was very real and not trivial. Whatever central effect was there felt overshadowed by feeling queasy for a couple hours. I mention it only because the online hype almost never leads with 'you might just feel sick,' and that side matters when you're weighing whether it's even worth exploring with a doctor.

This is exactly the calibration I needed, thank you both. So: one solid indication with modest effects, everything else more speculative, and a notable nausea signal. That reframes the marketing a lot for me.